DAY 1 (June 11)
6:00 PM Conference registration
7:30 PM Welcome Dinner
(Hotel check-in, networking and informal discussions)
CONFERENCE SESSIONS
DAY 2 (June 12)
|
8:00 AM |
|
Breakfast |
||
|
|
|
|
||
|
8:50 AM |
|
Welcome and Opening Remarks Dimitrios Mastellos (on behalf of the Organizing Committee) |
||
|
|
||||
|
SESSION I |
Structural insights and mechanisms of activation and regulation Chairs: Gregers Andersen, Doryen Bubeck |
|||
|
9:00 AM |
1 |
Structure determination of complement initiation: ‘caught in the act’ Thomas Sharp University of Bristol, UK |
||
|
9:20 AM |
2 |
Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring Gregers Andersen Aarhus University, Denmark |
||
|
9:40 AM |
3 |
Molecular insights into activation and signaling of the complement anaphylatoxin receptors Arun Shukla Indian Institute of Technology, Kanpur, India |
||
|
10:00 AM |
4 |
The complex complement modulatory role of the human factor H-related proteins Barbara Uzonyi, Alexandra Matola, Alexandra Papp, Marcell Cserhalmi, Hani Hammad, Dániel Bencze, Dávid Szakács, Veronika Barbai, Ádám Csincsi, Andrea Schneider, and Mihály Józsi Eötvös Loránd University, Hungary |
||
|
10:15 AM |
5 |
Regulating the complement membrane attack complex Doryen Bubeck Imperial College London, UK |
||
|
|
|
|
||
|
10:35 AM |
|
Coffee Break and Poster Viewing |
||
|
|
|
|
||
|
SESSION II |
Therapeutic development: novel complement inhibitors Chairs: Christina Lamers, Brian Geisbrecht |
|||
|
11:15 AM |
6 |
Inhibition of the C1s Protease and the Classical Complement Pathway by 6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs Brian Geisbrecht Kansas State University |
||
|
11:35 AM |
7 |
Insights into the molecular basis for inhibition of the classical pathway by C1 esterase inhibitor Brandon Garcia East Carolina University, USA |
||
|
11:55 AM |
8 |
Decommissioning the initiators: Therapeutic Interference in the early activation steps of the complement response Daniel Ricklin University of Basel, Switzerland |
||
|
12:15 AM |
9 |
History of a success: setting proximal complement inhibitors as new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria Antonio M. Risitano University of Napoli Federico II, Italy |
||
|
12:35 PM |
10 |
Therapeutic inhibition of complement C5aR1 is neuroprotective in Parkinson’ s disease preclinical models Eduardo Albornoz and Trent Woodruff The University of Queensland, Australia |
||
|
12:55 PM |
11 |
TBD Christina Lamers Leipzig University, Germany |
||
|
13:15 PM |
12 |
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies Laura Bracke, Tim Delahaye, Jolien Delaere, Karen De Winter, Emma Persson, Eline Haspeslagh, Ans Rombaut, and Inge Van de Walle Research and Development, Argenx BV |
||
|
13:30 PM |
13 |
Expanding the therapeutic scope of complement C3 inhibition: new paradigms and opportunities John D. Lambris Perelman School of Medicine, University of Pennsylvania, USA |
||
|
|
|
|
||
|
13:50 PM |
|
Lunch and Informal Discussions |
||
|
|
||||
|
7:30 PM |
|
Dinner and Informal Discussions |
||
|
|
|
|
||
|
|
DAY 3 (June 13) |
|
||
|
|
|
|
||
|
SESSION III |
Novel therapeutic concepts and mechanisms of inflammation Chairs: Anna Blom, George Hajishengallis |
|||
|
9:00 AM |
14 |
Maladaptive trained immunity and chronic inflammation George Hajishengallis Penn Dental Medicine, USA |
||
|
9:20 AM |
15 |
Bone-marrow mediated trained immunity Triantafyllos Chavakis Technical University Dresden, Germany |
||
|
9:40 AM |
16 |
Expression and activation of intracellular complement (complosome) in human and murine stem cells: a novel view on the biology of stem cells Mariusz Ratajczak University of Louisville, USA |
||
|
10:00 AM |
17 |
Protective functions of cytosolic C3 in pancreatic beta cells Anna Blom Lund University, Sweden |
||
|
10:20 AM |
18 |
Does C2b have a role in inflammation? Marco Mannes, Alina Dettner, Susa Savukoski, Christoph Schmidt, and Markus Huber-Lang University of Ulm, Germany |
||
|
10:35 AM |
19 |
TBD Marius Ueffing University of Tübingen, Germany |
||
|
10:55 AM |
|
Flash Poster session-A (35 min) |
||
|
11:30 AM |
|
Coffee Break and Poster Viewing |
||
|
|
|
|
||
|
|
||||
|
SESSION IV |
Preclinical models and interventions exploiting complement regulators Chairs: Inge Van de Walle, Gregory Hageman |
|||
|
12:15 PM |
20 |
Development of C3 humanized rats as preclinical models for evaluating novel human C3-targeted therapeutics Feng Lin Cleveland Clinic, USA |
||
|
12:35 PM |
21 |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide Christoph Schmidt University of Ulm, Germany |
||
|
12:55 PM |
22 |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH Mieke Brouwer, Anna van Beek, Gerard van Mierlo, Gillian Dekkers, Ilse Jongerius, Diana Wouters, Taco Kuijpers, and Richard Pouw University of Amsterdam, Netherlands |
||
|
13:10 PM |
23 |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration Dennis Keefe, Mustafa Munye, Athanasios Didangelos, Sofiya Pisarenka, Suhnrita Chaudhuri, Rachel Green, Peter Emery-Billcliff, Nakul Patel, Pamela Whalley, Parisa Zamiri, Simon Clark , and Paul Bishop Complement Therapeutics, UK |
||
|
|
|
|
||
|
13:25 PM |
Lunch and Informal Discussions |
|||
|
|
|
|
||
|
7:30 PM |
Dinner and Informal Discussions |
|||
|
|
|
|||
|
DAY 4 |
|
(June 14) |
||
|
|
|
|
||
|
SESSION V |
Targeting Complement in Cancer Chairs: Elena Magrini, Lubka Roumenina |
|||
|
8:45 AM |
24 |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment Brahm H. Segal Roswell Park Comprehensive Cancer Center, USA |
||
|
9:05 AM |
25 |
The role of C1q and gC1qR as a novel checkpoint in cancer Berhane Ghebrehiwet Stony Brook University, USA |
||
|
9:25 AM |
26 |
Complement-related proteins for diagnosis, prognosis and prediction of response in cancer Ruben Pio CIMA-University of Navarra, Spain |
||
|
9:45 AM |
27 |
Intracellular C1r promotes kidney cancer progression Nicolas Merle, Mikel Rezola Artero, Alessandra Zarantonello, Artemis Angelidou, Margot Revel, Idris Boudhabhay, Christine Gaboriaud, and Lubka Roumenina Cordeliers Research Center, Sorbonne University, France |
||
|
10:00 AM |
28 |
The role of complement in pancreatic cancer: from complement activation triggering and effector mechanism/s to combination with classical therapies Monica Dambra, Giovanni Pezone, Alberto Mantovani, Elena Magrini, and Cecilia Garlanda Humanitas University, Italy |
||
|
10:15 AM |
29 |
The Role of Complement Receptor C5aR1 in a Murine Glioblastoma Model Jad Farouqa, Stefan Sonderegger , Chelsea Stewart, Eduardo Albornoz, Nadya Panagides, Jamileh Nabizadeh, and Barbara Rolfe University of Queensland, Australia |
||
|
10:30 AM |
30 |
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells Mikel Rezola Artero, Margot Revel, Alessandra Zarantonello, Andrea Minery Berenguer, Idris Boudhabhay, Jordan Dimitrov, Angela Armento, Mohamed Jarboui, Marius Ueffing, and Lubka Roumenina Cordeliers Research Center, Sorbonne University, France |
||
|
10:45 AM |
31 |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC Elena Magrini, Kevin Berthenet, Luna Minute, Monica Dambra, Fabio Grizzi, Roberta Carriero, Fabio Pasqualini, Sarah Mapelli, Sebastien Jaillon, Alberto Mantovani, and Cecilia Garlanda IRCCS Humanitas Clinical and Research Center, Milan, Italy |
||
|
11:00 AM |
|
Coffee Break and Poster Viewing |
||
|
|
|
|
||
|
SESSION VI |
Complement in inflammatory and autoimmune diseases Chairs: Hrishikesh Kulkarni and Despina Yancopoulou |
|||
|
11:45 AM |
32 |
The inflammatory landscape in peri-implantitis and host modulation therapeutic opportunities Georgios Kotsakis Rutgers School of Dental Medicine, USA |
||
|
12:05 PM |
33 |
TBD E. Sander Connolly Columbia University, USA |
||
|
12:25 PM |
34 |
TBD Christoph Binder Medical University of Vienna, Austria |
||
|
12:45 PM |
35 |
Is there a bright side of complement after trauma? Markus Huber-Lang, Rebecca Halbgebauer, Lisa Wohlgemuth, Marco Mannes University of Ulm, Germany |
||
|
13:05 PM |
36 |
C1q-mimiking scFv fragments binding anti-C1q autoantibodies modulate disease progression in MRL/lpr mouse model of Systemic Lupus Erythematosus Andrey Tchorbanov, Silviya Bradyanova, Nikolina Mihaylova, Nikola Ralchev, and Ivanka Tsacheva Bulgarian Academy of Sciences, Bulgaria |
||
|
13:20 PM |
Lunch and Informal Discussions |
|||
|
|
||||
|
15:30 PM |
|
(GUIDED CITY TOUR) |
||
|
7:30 PM |
Dinner and Informal Discussions |
|||
|
|
|
|||
|
DAY 5 |
(June 15) |
|||
|
SESSION VII |
Complement in organ transplantation and infectious diseases Chairs: Tom Mollnes, Matteo Stravalaci |
|||
|
9:00 AM |
37 |
Complement in chronic allograft dysfunction after lung transplantation Hrishikesh Kulkarni Washington University School of Medicine, St Louis, USA |
||
|
9:20 AM |
38 |
The Roles of Complement C3 and C5 in Pulmonary Antifungal Immunity Jigar Desai National Institute of Allergy & Infectious Diseases, NIH, USA |
||
|
9:40 AM |
39 |
Development of mannose binding lectin as therapeutic agent in COVID-19 Matteo Stravalaci IRCCS Policlinico Maggiore Hospital, Milan, Italy |
||
|
10:00 AM |
40 |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19 Christina Antoniadou, Anastasia-Maria Natsi, Dimitrios Mastellos, Evangelos Papadimitriou, Efstratios Gavriilidis, Victoria Tsironidou, Markus Huber-Lang, Antonio Risitano, Despina Yancopoulou, Georgios Germanidis, Panagiotis Skendros, Konstantinos Ritis, and John Lambris Democritus University of Thrace, Greece |
||
|
10:15 AM |
41 |
Concomitant deficiency of C5aR1 and C5aR2 drives neutrophil dysregulation resulting in increased susceptibility to pneumococcal infection Sarah Walachowski, Archana Jayaraman, Markus Dudek, Joshua Campbell, Joseph Mizgerd, and Markus Bosmann Boston University, USA |
||
|
10:30 AM |
42 |
Complement C5b-C8 and C5b-C9 membrane attack complexes differentially potentiate antimicrobial activity against drug-resistant Neisseria gonorrhoeae Evan Lamb and Alison Criss University of Virginia, USA |
||
|
10:45 AM |
|
Flash Poster session-B (15 min) |
||
|
11:00 AM |
|
Coffee Break and Poster Viewing |
||
|
|
|
|
||
|
SESSION VIII |
Kidney disease, biomarkers and complement diagnostics Chairs: Ashley Frazer-Abel, Peter Garred |
|||
|
11:30 AM |
43 |
In situ Complementomics reveals pathological intracellular action of complement C3 in diseases affecting the kidney Lubka Roumenina Centre de Recherche des Cordeliers, Sorbonne University, France |
||
|
11:50 PM |
44 |
Immune complex glomerulonephritis and C3 glomerulopathy in 2024: state of the art Richard Smith University of Iowa, USA |
||
|
12:10 PM |
45 |
TBD Felix Poppelaars University Medical Center of Groningen, Netherlands |
||
|
12:30 PM |
46 |
Renin in C3 Glomerulopathy by SomaScan Yuzhou Zhang and Richard Smith University of Iowa, USA |
||
|
12:45 PM |
47 |
Genome-wide association screening of complement activation: data from a general population study Damia Noce, Luisa Foco, Florian Kronenberg, Reinhard Würzner, and Cristian Pattaro Medical University of Innsbruck, Austria |
||
|
13:00 PM |
48 |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy Klaudia Kulak, Viktoria Kozma, Cecilia Klint, Camilla Nilsson, Jordi Rodo, Samuel Butler, Ali Qamar, and Michael Schwenkert Svar Life Science, Sweden |
||
|
13:15 PM |
|
|
||
|
13:30 PM |
|
Closing remarks Lubka Roumenina, Dimitrios Mastellos (On behalf of the organizing committee) |
||
|
|
|
|
||
|
13:45 PM |
|
Lunch and Informal Discussions |
||
|
|
|
|
||
|
8:00 PM |
Farewell dinner |
|||
|
DAY 6 |
(June 16) |
|
|
Departure day |
POSTERS
The conference will include 1-2 live poster sessions during which registered presenters will be able to give a 3-min ‘flash’ poster talk highlighting the main findings of their study.
1. Granzyme K activates a new complement pathway.
Carlos Donado, Erin Theisen, Anna Jonsson, and Michael Brenner
2. Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
Andrea Grioni, Mykola Lysetskiy, Anna Schubart, Marie-Anne Valentin, Dmitrij Kollins, Imelda Schuhmann, Anastasiia Zub, Oksana Ikkert, Oleksandr Karmash, and Yaryna Shalai
3. A method to determine the inhibitor potential of the blood to predict uncontrolled activation of the complement system
Batozhab Shoibonov
4. Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
Virginia Cianchi, Matteo Stravalaci, Isabel Pagani, Alessandro Ajò, Luisa De Cola, Elisa Vicenzi, Alberto Mantovani, and Cecilia Garlanda
5. Selective suppression of pathogenic B lymphocytes from Hashimoto's thyroiditis patients by chimeric protein molecules
Andrey Tchorbanov, Nikola Ralchev, Irini Doychinova, Iliyan Manoylov, Nikolina Mihaylova, and Alexander Shinkov
6. Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
Klaudia Kulak, Selvi Celik, Viktoria Kozma, Cecilia Klint, Benoit Vallette, Camilla Nilsson, Christophe Lallemand, Lone Bovin, Jordi Rodo, Samuel Butler, and Michael Schwenkert
7. Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
Ole Brekke, Ingrid Joakimsen, Baard Karlsen, Åse Emblem, Kristin Pettersen, Renathe Grønli, Corinna Lau, John Lambris, and Tom Mollnes
8. Investigating the impact of complement sources and Complement Factor H (CFH) Y402H polymorphism on the stress response of iPSC-RPE cells
Angela Armento, Inga Sonntag, Simon Clark, Rosario Fernandez-Godino, Berta de la Cerda, and Marius Ueffing
9. Selection and characterization of a peptide-based complement activator
Sebastiaan Hamers, Thomas Sharp, and Aimee Boyle
10. Titration of the biological activities Anaphylatoxins using reporter cell lines
Rosa Ferrando-Miguel and Emilie Gobbo
11. Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
Andrea Moreno-Amaral, Marina de Deus, Ana Carolina Gadotti, Gabriela Andrade, Erika Dias, Julia Monte Alegre, Beatriz Akemi Von Spitzenbergen, and Sara Tozoni
12. Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
Laura Bracke, Heidi Olesen, Erwin Pannecoucke, Tim Delahaye, Emma Persson, Erik Hack, Gregers Andersen, and Inge Van de Walle
13. Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected respiratory epithelial cells
Hang Zhong, Matteo Stravalaci, Isabel Pagani, Niloufar Kavian-Tessler , Poli Guido, Seppo Meri, Barbara Bottazzi, Elisa Vicenzi, and Cecilia Garlanda
14. CORVOS (2019-2024): facilitating more PhD student exchanges and working towards a European Complement PhD
Reinhard Würzner
15. Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1.
Sandra Wymann, Anup Nair, Svenja Ewert, Glenn Powers, Adriana Baz Morelli, Tony Rowe, and Matthew Hardy
16. Obesity and metabolic health shapes mucosal complement responses
Devesha Kulkarni, Khushi Talati, Ayse Ozanturk, Dalia Harris, Rafael Aponte, Hrishi Kousik, and Hrishikesh Kulkarni
17. Understanding the effects of ARMS2 and its AMD risk variant A69S on extracellular matrix and complement system
Merve Sen, Angela Armento, and Marius Ueffing
18. Targeting the Hypothalamic Complement System: A Novel Approach to Combatting Obesity
Carolin Gragoll, Timo Rusack, Michael Schneider, Ingo Eitel, Zouhair Aherrahrou, Elias Rawish